Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

“According to the writer, obesity seems to be a matter of lack—a lack of bariatric surgeries and a lack of Ozempic courtesy ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...

It’s not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisk’s diabetes ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Denmark's drug regulator asks EMA to investigate potential link between Novo Nordisk's diabetes drug Ozempic and rare eye ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two ...